To be fair to your idea, R/S are not always bad, but you have to be in the right situation. I know I was following equinox gold(EQX) when it was under a buck. When they finally were trending towards making revenue with good properties and top mgmt but had low visibility on the OTC in 2019, they wanted to uplist. It's turned out well for them, but they also have revenue now and a good set of properties. If cydy were to R/S we still don't meet the shareholders equity needed even if the price is above 4 bucks. HGEN initially got slaughtered because they also needed cash so they reversed and promptly diluted. Cydy would have to do the same. Right now I have no idea how close we are to approval or HIV BLA filings. If business for sure was on the upswing(significant rev, large PO, awaiting approval of a trial that met PE) and the market just wasn't taking notice, it's an option. If you're doing it like most companies who are desperate to stay listed on an exchange because they are heavily in debt and failing miserably...then you get the big crashes. Based on CYDYs financials we'll look like the desperate type.
The desperate R/S is the norm and not the exception. I'm not sure cydy has the ammo to get the interest yet, but the current volume is such that a truly worthy PR can get the company where it needs to be without the reverse.